Enterprise Value
34.47B
Cash
6.078B
Avg Qtr Burn
N/A
Short % of Float
1.83%
Insider Ownership
0.68%
Institutional Own.
90.87%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
QALSODY™ BIIB067 (tofersen) Details Amyotrophic lateral sclerosis | Approved Update | |
ZURZUVAE BIIB125 (zuranolone) Details Postpartum depression | Approved Quarterly sales | |
Leqembi (Lecanemab) (Aβ mAb) Details Alzheimer's disease | Approved Quarterly sales | |
TOFIDENCE (BIIB800) (tocilizumab), Details Polyarticular juvenile idiopathic arthritis, Rheumatoid arthritis | Approved Quarterly sales | |
ADUHELM™ / Aducanumab (Aβ mAb) Details Alzheimer’s disease | Approved Quarterly sales | |
SKYCLARYS™ (Omavaloxolone) Details Friedreich’s Ataxia | Approved Quarterly sales | |
Dapirolizumab pegol Details Systemic lupus erythematosus | Phase 3 Data readout | |
BIIB080 (tau ASO) Details Alzheimer's disease | Phase 2 Data readout | |
ATXN2 ASO (BIIB105) Details Amyotrophic lateral sclerosis | Phase 1/2 Data readout | |
IONS582 /BIIB121 Details Angelman Syndrome | Phase 1b Data readout | |
BIIB093 (IV glibenclamide) Details Acute myocardial infarction | Failed Discontinued | |
SB15 (biosimilar referencing EYLEA®) Details no known indication | Failed Discontinued | |
BIIB074 (vixotrigine) Details no known indication | Failed Discontinued |